Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 2 of the 76 sources its claims cite were checked for support.
Abstract
As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, we investigated after long-term follow-up whether mutation status influenced the rate of ipsilateral and contralateral breast cancers after breast-conserving treatment (BCT). BRCA1 and BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer who had undergone BCT and radiotherapy. Patients were matched to 261 controls with sporadic breast cancer according to age at diagnosis and year of treatment. Controls were followed up for at least as long as the interval between diagnosis and genetic screening in familial cases. Rates of ipsilateral and contralateral cancer between groups were compared by the log-rank test. The BRCA1/2 mutations occurred in 20.6% of tested patients. Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. Overall median follow-up was 161 months. There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and controls (P = 0.13). On multivariate analysis, age was the most significant predictor for ipsilateral recurrence (P < 10(-3)). The rate of contralateral cancer was significantly higher in familial cases: 40.7% (mutation carriers), 20% (non-carriers), and 11% (controls) (P < 10(-4)). After 13.4 years of follow-up, the rate of ipsilateral tumours was no higher in mutation carriers…
Overview
CoChat Summary
## TL;DR
This matched retrospective single-institution study found that, after a median follow-up of 13.4 years, BRCA1/2 mutation carriers had no higher ipsilateral breast tumor recurrence after breast-conserving treatment plus radiotherapy than non-carriers or sporadic controls. However, contralateral breast cancer was significantly more common in carriers, so breast-conserving treatment remained a possible option but with caution and risk-reduction discussion.
## Key findings
- Among 131 screened patients, 27 (20.6%) carried a BRCA mutation: 19 BRCA1 and 8 BRCA2.
- Median follow-up was 161 months overall (167 months in carriers, 161 months in non-carriers, 156 months in controls), and there was no significant difference in ipsilateral tumor recurrence among groups (P = 0.13) or between carriers and matched controls (P = 0.43).
- Tumors in mutation carriers were more often grade III (P < 10^-4) and hormone receptor negative (estrogen receptor P = 0.018, progesterone receptor P = 0.02) than in non-carriers or controls.
- Contralateral breast cancer was significantly higher in BRCA carriers: 40.7% in carriers versus 20.2% in familial non-carriers versus 11.1% in sporadic controls (P < 10^-4). In multivariate analysis, BRCA mutation status was the only significant predictor of contralateral cancer (P < 10^-4), while age was the only significant predictor of local recurrence (RR 1.05 [1.02–1.07] per decreasing year of age; P < 10^-3).
## Methods
- Retrospective matched case-control study at Institut Curie of women with small breast cancers treated with breast-conserving surgery and radiotherapy between 1981 and 2000.
- 131 patients with a family history of breast/ovarian cancer were genetically screened; they were matched to 261 sporadic controls by age at diagnosis, year of treatment, and follow-up period.
- Survival and recurrence outcomes were analyzed with Kaplan–Meier, log-rank tests, and Cox proportional hazards models adjusting for age, nodal status, receptor status, and grade.
## Limitations
- The paper states the main weakness is the limited number of patients and the retrospective nature of the study.
- Evident from the text: some analyses were limited by missing data/not determined values and the small number of events in subgroups, and the authors note that the effect of tamoxifen on contralateral risk was not studied because of the high number of receptor-negative tumors.
- Evident from the text: the cohort is from a single institution, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
2 Valid · 1 Not valid · 19 Not checked · 27 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“All studies of BRCA1 and/or BRCA2 mutation carriers so far have reported an increased incidence of contralateral breast cancer [9, 15, 28-30, 37, 38, 40].”
What the sources say
- Supportedcites [9] Robson M, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17 source
Robson et al. (2003) report exactly the finding the citing sentence attributes to it: in the Results (Ipsilateral and contralateral breast cancer) women with mutations were significantly more likely to develop contralateral breast cancer at 10 years (27% vs 8%; P < 0.0001), with similar risk in BRCA1 (27%) and BRCA2 (32%) carriers. The Discussion states 'Women with BRCA1/BRCA2 mutations are at substantial increased risk for metachronous contralateral breast cancer throughout the follow-up period,' and notes this rate is similar to that observed in affected carriers after mastectomy [29] and in prospectively followed heterozygote cohorts [30,31]; the Conclusion repeats that 'the risk for contralateral disease is substantially higher.' Nothing in our copy contradicts an increased contralateral incidence, so this source supports the generalization (the 'all studies so far' scope is the citing authors' own framing, but every element attributed here — BRCA1 and/or BRCA2 carriers, increased contralateral breast cancer incidence — is stated in the paper). (LLM, conf=0.85)
- Not checked yetcites [15] Cortez D, Wang Y, Qin J et al (1999) Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science 286:1162–1166 source
- Not checked yetcites [28] Kirova YM, Stoppa-Lyonnet D, Savignoni A et al (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41:2304–2311 source
- Not checked yetcites [29] Pierce LJ, Strawderman M, Narod SA et al (2000) Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18:3360–3369 source
- Not checked yetcites [30] Pierce L, Levin A, Rebbeck T et al (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24:2437–2443 source
- Not checked yetcites [37] Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/BRCA2 status. Lancet 359:1471–1477 source
- Not checked yetcites [38] Seynaeve C, Verhoog LC, Van De Bosch LM et al (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158 source
- Not checked yetcites [40] Turner BC, Harrold E, Matloff E et al (1999) BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 17:3017–3024 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Robson et al. [9] reported a 27% risk in carriers versus an 8% risk in non-carriers ( P = 0.002) after 10 years of follow-up.”
What the sources say
- Partly supportedcites [9] Robson M, Chappuis PO, Satagopan J et al (2004) A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8–R17 sourceExperimental — accuracy not yet measured
The Results section (‘Ipsilateral and contralateral breast cancer’) reports a 10-year contralateral breast cancer risk of 27% in mutation carriers versus 8% in non-carriers. It gives P < 0.0001 for that comparison, not P = 0.002; the latter value refers to age under 50 as a predictor of ipsilateral disease. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and controls ( P = 0.13).”
- Also stated in: § Results · plain
“There was no significant difference in ipsilateral tumour recurrence amongst groups ( P = 0.13) nor between mutation carriers and their matched controls ( P = 0.43)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The BRCA1/2 mutations occurred in 20.6% of tested patients.”
- Also stated in: § Results · plain
“Twenty-seven patients (20.6%) with a family history of breast cancer had a BRCA mutation (19 BRCA1 , 8 BRCA2 ) (21.3% tumours).”
plainn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant difference in the overall survival between the three groups (Fig. 3).”
- Also stated in: § Discussion · plain
“At the same time, there was no difference in the overall survival in the different groups of patients.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
24 more claims
Create a free account to see all 49 claims and to verify the 74 references still open.
- It may state two separate claims as one. 10
- Probably not a substantial claim. 13
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · cited 1×
“The influence of BRCA mutation, adjusted for other prognostic factors, was assessed in a multivariate analysis by the Cox proportional hazards model, in a forward stepwise regression procedure [ 52 ].”
MethodEvaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Gene-Expression Profiles in Hereditary Breast Cancer
Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Raffeld, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440801 · Cited by 1,733
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
van Dongen, J. A. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1143 · Cited by 1,271
Easton, D. F., Bishop, D. T., Ford, D., & Crockford, G. P. (1993) · Europe PMC (PubMed Central) · Cited by 1,243
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Cortez, D., Wang, Y., Qin, J., & Elledge, S. J. (1999) · Science · doi:10.1126/science.286.5442.1162 · Cited by 1,020
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Claus, E. B., RISCH, N. J., & Thompson, W. D. (1991) · PubMed · Cited by 911
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80503-6 · Cited by 900
Jacobson, J. A., Danforth, D. N., Cowan, K. H., d'Angelo, T., Steinberg, S. M., Pierce, L., Lippman, M. E., Lichter, A. S., Glatstein, E., & Okunieff, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321402 · Cited by 892
Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X.-W., Harris, C. C., Ried, T., & Deng, C.-X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80466-9 · Cited by 819
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Self-citationStratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 543
Self-citation山口, 博. (2006) · Mebio oncology · Cited by 516
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Clark, R. M., McCulloch, P. B., Levine, M. N., Lipa, M., Wilkinson, R. H., Mahoney, L. J., Basrur, V. R., Nair, B. D., McDermot, R. S., Wong, C. S., et al. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.9.683 · Cited by 395
Powell, S. N., & Kachnic, L. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206678 · Cited by 364
Pierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340 · cited 2×
“and sporadic cases matched by age and date of diagnosis (n = 469) after a median follow-up of 8.3 years, reported by Pierce et al. [ 30 ].”
BackgroundInfluentialRobson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307 · cited 2×
“Table 4 are contradictory, no significant difference being found in the Robson et al. study unlike in the Haffty et al. study of a subgroup of 127 patients under 42 years of age [ 9 , 37].”
BackgroundInfluentialOutcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307 · cited 2×
“Table 4 are contradictory, no significant difference being found in the Robson et al. study unlike in the Haffty et al. study of a subgroup of 127 patients under 42 years of age [9, 37 ].”
BackgroundInfluentialPresymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
Meijers-Heijboer, E., Verhoog, L., Brekelmans, C., Seynaeve, C., Tilanus-Linthorst, M., Wagner, A., Dukel, L., Devilee, P., van den Ouweland, A., van Geel, A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02347-3 · Cited by 307
Pierce, L. J., Strawderman, M., Narod, S. A., Oliviotto, I., Eisen, A., Dawson, L., Gaffney, D., Solin, L. J., Nixon, A., Garber, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3360 · Cited by 268
Kirova, Y. M., Vilcoq, J. R., Asselain, B., Sastre‐Garau, X., & Fourquet, A. (2005) · Cancer · doi:10.1002/cncr.21223 · Cited by 251
Self-citationBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233 · cited 1×
“The more recent publication of the same team reported by Brekelmans et al. [ 31 ] showed no difference in term of ipsilateral breast recurrence, P = 0.6 between carriers and controls.”
ResultInfluentialDenaturing High-Performance Liquid Chromatography Detects Reliably BRCA1 and BRCA2 Mutations
Wagner, T., Stoppa-Lyonnet, D., Fleischmann, E., Muhr, D., Pagès, S., Sandberg, T., Caux, V., Moeslinger, R., Langbauer, G., Borg, A., et al. (1999) · Genomics · doi:10.1006/geno.1999.6026 · Cited by 224
Self-citationBrodie, S. G., Xu, X., Qiao, W., Li, W.-M., Cao, L., & Deng, C.-X. (2001) · Oncogene · doi:10.1038/sj.onc.1204929 · Cited by 188
Arriagada, R., Lê, M. G., Guinebretière, J.-M., Dunant, A., Rochard, F., & Tursz, T. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg452 · Cited by 179 · cited 1×
“As reported earlier, the familial and sporadic cohorts were well matched with regard to age at diagnosis [ 26 ].”
BackgroundFamilial Invasive Breast Cancers: Worse Outcome Related to BRCA1 Mutations
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., Clough, K. B., Magdelénat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4053 · Cited by 174
Self-citationClinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer
Chappuis, P. O., Nethercot, V., & Foulkes, W. D. (2000) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(200006)18:4<287::aid-ssu3>3.0.co;2-5 · Cited by 155
Stoppa‐Lyonnet, D., Laurent‐Puig, P., Essioux, L., Pagès-Berhouet, S., Ithier, G., Ligot, L., Fourquet, A., Salmon, R. J., Clough, K. B., Pouillart, P., et al. (1997) · Europe PMC (PubMed Central) · Cited by 155
Self-citationBaeyens, A., Thierens, H., Claes, K., Poppe, B., Messiaen, L., De Ridder, L., & Vral, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600628 · Cited by 136
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129 · cited 4×
“This analysis was planned in our previously reported study of homogeneous population of BRCA1/2 mutation carriers and their controls, treated at the Institut Curie [ 28 ].”
BackgroundMethodResultInfluentialSelf-citationSecond malignancies after breast cancer: the impact of different treatment modalities
for the Institut Curie Breast Cancer Study Group, Kirova, Y., Rycke, Y. D., Gambotti, L., Pierga, J., Asselain, B. J. R., & Fourquet, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604241 · Cited by 125
Self-citationTurner, B. C., Harrold, E., Matloff, E., Smith, T., Gumbs, A. A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P. M., Thomas, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3017 · Cited by 109
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100 · cited 1×
“young patients by Garcia-Etienne et al. [ 41 ] suggested after median follow-up of 4 years increased rates of ipsilateral breast cancer incidence in mutation carriers (9.3 vs. 2.5%) without complete information concerning the radiotherapy modalities (total dose, boost to the tumour bed) is given.”
BackgroundInfluentialCampana, F., Kirova, Y., Rosenwald, J., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.051 · Cited by 99
Self-citationIpsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy
Seynaeve, C., Verhoog, L. C., van de Bosch, L. M. C., van Geel, A. N., Menke-Pluymers, M., Meijers-Heijboer, E. J., van den Ouweland, A. M. W., Wagner, A., Creutzberg, C. L., Niermeijer, M. F., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.017 · Cited by 93 · cited 1×
“Matched cohort study described increased recurrence, after adjustment for age, in the hereditary group at 5 years but no significant increase in the 26 BRCA1/2 mutation carriers compared to sporadic cases [ 38 ].”
BackgroundPrimary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86
Adem, C., Reynolds, C., Soderberg, C. L., Slezak, J. M., McDonnell, S. K., Sebo, T. J., Schaid, D. J., Myers, J. L., Sellers, T. A., Hartmann, L. C., et al. (2003) · Cancer · doi:10.1002/cncr.11048 · Cited by 85
Danish Breast Cancer Cooperative Group.
Keiding, N., Kw, A., Andersen, J. A., et al. (1982) · PubMed · Cited by 80
How to Boost the Breast Tumor Bed? A Multidisciplinary Approach in Eight Steps
Kirova, Y., Fournier‐Bidoz, N., Servois, V., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.12.059 · Cited by 77
Self-citationKirova, Y., Servois, V., Campana, F., et al. (2006) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2006.05.014 · Cited by 62
Self-citationThe Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Drew, Y., & Calvert, H. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1414.020 · Cited by 61 · cited 1×
“BRCA1/2 mutations are responsible for the majority of genetic breast/ovarian cancers, known as the hereditary breast ovarian cancer syndrome [ 57 ].”
BackgroundLow expression of bcl-2 in Brca1-associated breast cancers
Freneaux, P., Stoppa-Lyonnet, D., Mouret, E., Kambouchner, M., Nicolas, A., Zafrani, B., Vincent-Salomon, A., Fourquet, A., Magdelenat, H., & Sastre-Garau, X. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1438 · Cited by 51
Self-citationFourquet, A., Stoppa‐Lyonnet, D., Kirova, Y., Sigal‐Zafrani, B., & Asselain, B. J. R. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31817f9e1c · Cited by 51
Self-citationRobson, M. E. (2002) · Cancer Control · doi:10.1177/107327480200900602 · Cited by 38
Contralateral Prophylactic Mastectomy: Caveat Emptor
Recht, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0518 · Cited by 25 · cited 1×
“The issue is complex and has been masterly addressed in a recent article [ 56 ].”
BackgroundRadiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
Pierce, L. (2002) · Seminars in Radiation Oncology · doi:10.1053/srao.2002.35254 · Cited by 17
Salmon, R. J., Asselain, B. J. R., Gal, M. L., & Fourquet, A. (1997) · The Breast · doi:10.1016/s0960-9776(97)90574-9 · Cited by 9 · cited 1×
“Controls were randomly selected from our prospective breast cancer registry of 9179 patients who underwent conservative treatment between 1981 and 2000, as reported earlier [28, 46 ].”
MethodSelf-citationSavignoni, A., Kirova, Y., Fourquet, A., & Sigal‐Zafrani, B. (2006) · American Journal of Immunology · doi:10.3844/ajisp.2006.61.63 · Cited by 4 · cited 1×
“The risk of second cancers in this population of patients is insufficiently documented [35, 36 ].”
BackgroundSelf-citation
Cited by
Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
“However previous studies in breast cancer have failed to show a relevant difference in local relapse or toxicity following radiation therapy (RT) compared with noncarriers [7–9].”
ResultTung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Valachis, A., Nearchou, A. D., & Lind, P. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2890-1 · Cited by 178
“Few data were available about the prognosis of carriers versus non-carriers after BCT since only three studies presented survival data [10, 15, 22].”
BackgroundMethodResultInfluentialvan den Broek, A. J., Schmidt, M. K., Veer, L. V. ‘., Tollenaar, R. A. �. �., & van Leeuwen, F. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120189 · Cited by 146
BRCA1/BRCA2Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
Lee, A., Moon, B.-I., & Kim, T. H. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.2.114 · Cited by 173
Metadata
- Authors
- Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A.
- Affiliations
- Institut Curie (FR)
- Corresponding author
- Kirova, Youlia M.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2009-12-24
- Volume
- 120
- Issue
- 1
- Pages
- 119-126
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2072876845
- Cited by
- 102
- References
- 58
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 8 · 2013: 9 · 2012: 6
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.science
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- breast-conserving therapy, BRCA1 mutation, BRCA2 mutation, germline mutation carriers, radiotherapy, ipsilateral breast cancer recurrence, contralateral breast cancer, radiosensitivity, hereditary breast cancer, tumor grade, long-term follow-up
- MeSH terms
- Adult, Age Factors, Breast Neoplasms, Combined Modality Therapy, Female, Heterozygote, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Mastectomy, Segmental, Incidence, Case-Control Studies, Neoplasms, Second Primary, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

